Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibody-based products coupled with the unmet need in infectious disease will likely exceed the current exi...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Livro |
| Publicado em: |
Taylor & Francis Group,
2022-04-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_18e705d77c1c49f3b407847b94f3f1b6 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Kevin J Whaley |e author |
| 700 | 1 | 0 | |a Larry Zeitlin |e author |
| 245 | 0 | 0 | |a Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing |
| 260 | |b Taylor & Francis Group, |c 2022-04-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2021.1930847 | ||
| 520 | |a This review focuses on the emerging monoclonal antibody market for infectious diseases and the metric ton scale manufacturing requirements to meet global demand. Increasing access to existing antibody-based products coupled with the unmet need in infectious disease will likely exceed the current existing global manufacturing capacity. Further, the large numbers of individuals infected during epidemics such as the ongoing COVID-19 pandemic emphasizes the need to plan for metric ton manufacturing of monoclonal antibodies by expanding infrastructure and exploring alternative production systems. | ||
| 546 | |a EN | ||
| 690 | |a monoclonal | ||
| 690 | |a passive immunization | ||
| 690 | |a manufacturing | ||
| 690 | |a scale | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 18, Iss 2 (2022) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2021.1930847 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/18e705d77c1c49f3b407847b94f3f1b6 |z Connect to this object online. |